Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP1 | P53582 | 7/20 | 0.69 |
| ▸ | METAP2 | P50579 | 3/20 | 0.50 |
| ▸ | PYGL | P06737 | 8/20 | 0.42 |
| ▸ | PYGM | P11217 | 6/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
| ▸ | F11 | P03951 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4497926 | 1.00 | METAP1 (0.69) | METAP1METAP2PYGLPYGMEPHX2 | |
| SCHEMBL4491714 | 0.92 | METAP1 (0.65) | METAP1METAP2PYGLPYGM | |
| SCHEMBL13818349 | 0.92 | METAP1 (0.65) | METAP1METAP2PYGLPYGM | |
| SCHEMBL4491725 | 0.92 | METAP1 (0.65) | METAP1METAP2PYGLPYGM | |
| SCHEMBL13818427 | 0.92 | METAP1 (0.65) | METAP1METAP2PYGLPYGM | |
| SCHEMBL2238145 | 0.87 | METAP1 (0.61) | METAP1METAP2EPHX2 | |
| SCHEMBL12345836 | 0.87 | METAP1 (0.61) | METAP1METAP2EPHX2 | |
| SCHEMBL2238149 | 0.87 | METAP1 (0.61) | METAP1METAP2EPHX2 | |
| SCHEMBL2238129 | 0.87 | METAP1 (0.61) | METAP1METAP2EPHX2 | |
| SCHEMBL4494589 | 0.84 | METAP1 (0.58) | METAP1METAP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7550453-B2 | Anticancer agents; colon cancer or hepatocellular carcinoma; analogs of bengamide where the caprolactam ring is changed and/or substituted e.g. N-(2-Methyl-3-oxo-2,3,4,5-tetrahydro-1H-2-benzazepin-4-yl)-(E)-(2R,3R,4S,5R)-3,4,5-trihydroxy-2-methoxy-8,8-dimethylnon-6-enamide | AVENTIS PHARMA SA (FR) | 2009-06-23 | — | — | US | disclosed |
| US-20070244087-A1 | 2-ALKOXY-3,4,5-TRIHYDROXY-ALKYLAMIDES, PREPARATION THEREOF, COMPOSITIONS CONTAINING THEM AND USE THEREOF | AVENTIS PHARMA S.A. (FR) | 2007-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070244087-A1 | 2-ALKOXY-3,4,5-TRIHYDROXY-ALKYLAMIDES, PREPARATION THEREOF, COMPOSITIONS CONTAINING THEM AND USE THEREOF | HCCS, ALKBH2, ALKBH3 | METAP1 3892/4885METAP2 3038/4885PYGL 1766/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.